• Disease Description


    Type 1 diabetes mellitus is a medical condition that occurs when the pancreas, an organ in the abdomen, produces very little or no insulin. Insulin, a hormone that helps the body to absorb and use glucose (sugar). Without insulin, blood glucose levels become higher than normal.


    Type 1 diabetes mos often develops when the immune system destroys the insulin-producing cells (beta-cells) in the pancreas. This is called an autoimmune response. The cause of this abnormal immune response is still not completely understood.


    This process can take time to occur, and initially there may be no symptoms of diabetes. High blood sugar and its associated symptoms (frequent urination, thirst) do not usually occur until more than 90 percent of the cells that make insulin have been destroyed. . Type 1 diabetes usually begins in childhood or young adulthood, but can develop at any age.


    Type 1 diabetes can develop in people with a family history of type 1 diabetes, but it also develops in people with no family history of diabetes. In either case, people who develop diabetes have one or more genes that make them susceptible to the disease. Environmental factors, such as exposure to certain viruses and foods early in life, might trigger the autoimmune response. [1]


    Prevalence


    In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. Diabetes remains the 7th leading cause of death in the United States in 2010. In the United States, Canada, and Europe, type 1 diabetes accounts for 5 to 10 percent of all cases of diabetes [1]


    Current Treatment Options


    Insulin treatment is one component of a diabetes treatment plan for people with type 1 diabetes. Insulin treatment replaces the body's own insulin, and aims to restore normal or near-normal blood sugar levels. With a little extra planning, people with diabetes who take insulin can lead a full life and keep their blood sugar under control.[1]


    Evidence for and Proposed Mechanism for Cannabinoid Therapies


    It was found that CBD treatment of 6- to 12-week-old mice significantly reduces the incidence of diabetes from 86% in nontreated control mice to 30% in CBD-treated mice. Results indicated that CBD can inhibit and delay destructive insulitis and inflammatory Th1-associated cytokine production in mice, resulting in a decreased incidence of diabetes possibly through an immunomodulatory mechanism shifting the immune response.[2] Research strengthens the previous assumption that CBD, known to be safe in humans, can possibly be used as a therapeutic agent for treatment of type 1 diabetes.[2]


    1. UpToDate online resource


    2. Weiss L, Zeira M, Reich S et al (2006) Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39:143–151

  • Category
    Critical Ailments
  • Created
    Thursday, 16 March 2017
  • Group admin
    CBIS

American States University

 CSi_Updates_Outline2.jpgDrug Valuation Image3


 

 Recent GBXI News:

June 22, 2023, GBX International Group, Inc., (OTC: GBXI)
Breaking Cancer Barriers; Investments in Low-Cost, Harvard Award-Winning, Effective Cancer Killing Drugs Now; GBXI Proceeds to Raise $1 Million to Fast-Track its' Success, Cancer Drug Valuations, Access for Patients, Full Company Audit, and Accelerate the Trading of the CSi-Spinout Shares

 

May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets


April 21, 2023, GBX International Group, Inc., (OTC: GBXI)

HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans 



Harvard GHC Award RCD 2018

 

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

 

Click here to review the Report:

Frontiers Capture
1mmStrong July 8 Court UPDATE Brochure Image

Sac Court Capture

Case No. 2:17-CV-02271-KJM-JDP



Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB
 



Observational Studies

PART

Notifications

Activity Stream

Hi Raymond,

As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase...
Show more

György Beck As Francis wrote: "It is simply taking a very long though." That's why a weekly update would be appreciated. 6 days ago
loader
loader
Attachment
Francis Cormier I personally do not think that weekly updates are productive. It takes time away from doing the work to be done. But, Bi-weekly Progress Updates... Show more 5 days ago
loader
loader
Attachment
Francis Cormier What I am waiting for is the Announcement for the Upcoming Public Fundraising Event reported previously; to be happening with a TBD date. I am... Show more 5 days ago
loader
loader
Attachment
RENE RAMIREZ How about a chart that shows action items with status and anticipated completion dates, 22 hours 12 minutes ago
loader
loader
Attachment
grant r smith raymond - are the new shares that will be issued to us as each company comes online come to us before or after they start trading? 4 hours 28 minutes ago
loader
loader
Attachment

Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"

HARVARD Award Winning 
CANCER Killing Success





1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

Frontiers_1.JPG


2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

 Frontiers_2.JPG


*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

WhatsApp_Image_2022-05-21_at_9.37.37_AM_3.jpg
Skin Cancer 

WhatsApp_Image_2022-05-21_at_9.37.38_AM.jpeg
Karposis Sarcoma

WhatsApp_Image_2022-05-21_at_9.37.38_AM_1.jpeg

CSi Final GIFT Share Issuance Nov 27 2022



Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

 LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

ASU/CSi-EDP-ECO-System
At it's FINEST !!! 

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.



2023 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2023

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296

Class A Common Stock
Authorized:
100,000,000
Issued:
0

Class B Common Stock
Authorized:
1,500,000,000
Issued:
0

Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000



Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE




*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!

 

Events

Sorry, we currently have no events.
View All Events